

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**BUSINESS UPDATE IN CONNECTION WITH
COMPLETION OF DISPOSAL OF SUBSIDIARIES**

Reference is made to the announcement of WuXi AppTec Co., Ltd. (the “**Company**”) dated October 24, 2025 (the “**Announcement**”) in connection with the disposal by WXAT Shanghai and the acquisition by Hillhouse of all of the shares in WuXi Clinical and WuXi MedKey. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As of the date of this announcement, WXAT Shanghai has received the first instalment payment of the consideration in the amount of RMB1.54 billion from Hillhouse pursuant to the terms of the SPA, the conditions precedent to completion as set out in the SPA have been satisfied, and the Transaction has been completed. As a result, WuXi Clinical and WuXi MedKey are no longer covered in the Company’s consolidated financial statements. WuXi Clinical, WuXi MedKey and other relevant parties will carry out the share transfer registration procedures for WuXi Clinical and WuXi MedKey in connection with the Transaction under the agreements of the SPA, and such procedures are expected to be completed by December 31, 2025.

As preliminarily calculated by the Company’s finance department in accordance with the China Accounting Standards for Business Enterprises (the “**CAS**”), the Transaction is expected to generate net profit after tax of approximately RMB0.96 billion, representing over 10% of the net profit attributable to the shareholders of the Company for the most recent period (i.e., the year of 2024). The Company will account for such investment income in accordance with applicable regulations including the CAS and the International Financial Reporting Standards, with the definitive amount subject to the annual audit by the auditors. The transaction parties are required to continue performing their respective obligations under the SPA.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, December 15, 2025

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*